WILLIAM E. ROTE
CIK 1698262 · Chief Research Officer · last filed 2026-05-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.77M
Companies
2
Total Filings
61
Lifetime Open-Market Net
-$5.22M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | Chief Research Officer | 118,237 | $65.71 | $7.77M | -$4.65M | 28 | 2026-05-06 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Senior Vice President, R&D | 24,086 | — | — | -$567.0K | 19 | 2020-11-17 |
Recent Filings · Page 5 of 7
61 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-02-02 | TVTX | Mixed | +1,375 | -$111.5K | EDGAR |
| 2021-01-25 | TVTX | Grant (A) | +15,000 | $0 | EDGAR |
| 2020-11-17 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −2,500 | -$59.9K | EDGAR |
| 2020-11-13 | Travere Therapeutics, Inc. (RTRX) Delisted | Mixed | +2,500 | -$59.1K | EDGAR |
| 2020-09-23 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −1,500 | -$27.7K | EDGAR |
| 2020-09-22 | Travere Therapeutics, Inc. (RTRX) Delisted | Mixed | +1,500 | -$27.9K | EDGAR |
| 2020-05-13 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −2,152 | -$35.0K | EDGAR |
| 2020-03-12 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −3,250 | -$48.3K | EDGAR |
| 2020-03-09 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +3,250 | $0 | EDGAR |
| 2020-02-19 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −2,500 | -$41.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.